vunakizumab
Monoclonal antibody
Also known as SHR-1314
Evidence outlook
Approved: Active ankylosing spondylitis with poor response to conventional treatment (CN)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Caveat: this result is taken from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025, PMID 39332633); the ClinicalTrials.gov record (status unknown) has no posted results.
track record: Reliable signal
Also in development:Psoriatic Arthritis · Phase 3 · investigational in the US
Also approved (2)
- Active ankylosing spondylitis with poor response to conventional treatment
- Moderate to severe plaque psoriasis
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04839016 NCT04839016 · Moderate-to-Severe Plaque Psoriasis This randomized, double-blind, placebo-controlled Phase 3 trial randomized 690 patients with moderate-to-severe plaque psoriasis 2:1 to vunakizumab 240 mg or placebo. The co-primary endpoints were PASI 90 and sPGA 0/1 at week 12. PASI 90 was reached by 76.8% of patients on vunakizumab and 0.9% on placebo, and sPGA 0/1 by 71.8% and 0.4% (both two-sided P < .0001), so both co-primary endpoints were met. The registry record still shows its 2021 estimated enrollment of 660 and has no posted results; the figures come from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025). Caveat: this result is taken from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025, PMID 39332633); the ClinicalTrials.gov record (status unknown) has no posted results. Registry: NCT04839016 | 3 | Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90) at Week 12; sPGA of 0 or 1 response at Week 12 2023-08-30 | Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). | Reliable signal | link ↗ |
View 2 more trials
NCT06833307 NCT06833307 · Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis Registry: NCT06833307 | 3 | Safety assessment including adverse events at Week 16; PK parameters: Cmax at Week 12 2026-07 | In progress: primary completion was expected 1 Jul 2026; results not posted | not yet graded | link ↗ |
NCT03463187 NCT03463187 · Moderate-to-severe Chronic Plaque Psoriasis This randomized, quadruple-blind, placebo-controlled Phase 1/2 trial (n=211) in moderate-to-severe plaque psoriasis found dose-dependent, highly significant improvement with vunakizumab: 57% to 87% of patients across the doses tested achieved at least 75% clearance of psoriasis (PASI75) at week 12, compared with 5.4% on placebo (p<0.001 for every dose). Registry: NCT03463187 | 1/2 | Percentage of participants achieving PASI 75 (Part B) (week 12) 2020-08-31 | PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other IL-17 drugs
ixekizumab, secukinumab, netakimab. Compare all 4 IL-17 drugs
3 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Psoriatic Arthritis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vunakizumab: this drug | Phase 3 | Monoclonal antibody | IL-17 | Partial signal | NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively | |
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | Reliable signal | NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | Reliable signal | NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3% NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19% | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Reliable signal | NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results). | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | Reliable signal | NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001 | |
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Reliable signal | NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001) | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2% | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Ixekizumab (Taltz) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results). | |
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | Partial signal | No reviewed efficacy summary in this indication | |
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5) NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Icotrokinra (Icotyde) | Phase 3 | Peptide | IL-23 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Netakimab | Phase 3 | Monoclonal antibody | IL-17 | Reliable signal | NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | Partial signal | NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled) | |
| Tirzepatide (Zepbound) | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Zasocitinib | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10374 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| LPX-TI641 | Phase 1 | Small molecule | TIM receptor (Treg-expanding) | not yet graded | No reviewed efficacy summary in this indication | |
| S-4321 | Phase 1 | Multispecific antibody | PD-1 / FcγRIIb (dual) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow vunakizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (1)
February 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent